No evidence of frequent association of the JAK2 V617F mutation with acute myocardial infarction in young patients

Leukemia

Volumn 23, Issue 5, 2009, Pages 1008-1009

  Politou, M ^a   Zoi, C ^b   Dahabreh, I J ^b,c   Rallidis, L ^a   Gialeraki, A ^a   Loukopoulos, D ^b   Zoi, K ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

ACUTE HEART INFARCTION; ADULT; AGE; ARTICLE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; MYELOPROLIFERATIVE DISORDER; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; THROMBOSIS;

EID: 67349259583     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.368     Document Type: Article

References (10)

1. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005; 128: 275-290.
2. Dahabreh IJ, Zoi K, Giannouli S, Zoi C, Loukopoulos D, Voulgarelis M. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res 2009; 33: 67-73.
3. Boissinot M, Lippert E, Girodon F, Dobo I, Fouassier M, Masliah C et al. Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis. Blood 2006; 108: 3223-3224.
4. Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: A report on 241 cases. Blood 2008; 111: 4922-4929.
5. Mercier E, Cochery-Nouvellon E, Lavigne G, Bertinchant JP, Gris JC. In support of the revised World Health Organization diagnostic criteria for essential thrombocythemia: JAK2 V617F and premature myocardial infarction. J Thromb Haemost 2008; 6: 206-207.
6. Pardanani A, Lasho TL, Hussein K, Schwager SM, Finke CM, Pruthi RK et al. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: Assessment of value in a series of 664 consecutive patients. Mayo Clin Proc 2008; 83: 457-459.
7. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162-2168.
8. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998; 17: 857-872.
9. Remacha AF, Estivill C, Sarda MP, Mateo J, Souto JC, Canals C et al The V617F mutation of JAK2 is very uncommon in patients with thrombosis. Haematologica 2007; 92: 285-286.
10. Pardanani A, Lasho TL, Schwager S, Finke C, Hussein K, Pruthi RK et al. JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder. Leukemia 2007; 21: 1828-1829.